Reldesemtiv - Astellas Pharma/Cytokinetics

Drug Profile

Reldesemtiv - Astellas Pharma/Cytokinetics

Alternative Names: CK-107; CK-2127107

Latest Information Update: 16 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytokinetics
  • Developer Astellas Pharma; Cytokinetics
  • Class Pyridines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Troponin tropomyosin complex stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Chronic obstructive pulmonary disease; Spinal muscular atrophy
  • Phase I Muscle fatigue
  • No development reported Muscular atrophy

Most Recent Events

  • 18 Jun 2018 Chemical structure information added
  • 16 Jun 2018 Efficacy, pharmacokinetics and adverse events data from a phase II trial in patients With Spinal muscular atrophy released by Cytokinetics
  • 08 Jun 2018 Astellas completes a phase IIa trial for Chronic obstructive pulmonary disease in USA (NCT02662582)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top